5
#000000
#FFFFFF
big pharma
Senate Republicans Block Sanders Amendment to Cut US Drug Prices by More Than 50%
Sen. Bernie Sanders said the amendment blocked by the GOP "would prevent pharmaceutical companies from charging more for prescription drugs in the United States than they do in Canada, the UK, Germany, France, and Japan."
Apr 23, 2026
Senate Republicans voted in the early hours of Thursday morning to reject an amendment offered by Sen. Bernie Sanders that aimed to cut US prescription drug prices in half by mandating that Americans pay no more for medications than people in Canada and other wealthy nations.
Just two Republicans, Sens. Josh Hawley of Missouri and Dan Sullivan of Alaska, voted with every present Democrat in support of Sanders' (I-Vt.) proposed amendment to the GOP's emerging budget reconciliation package. Republicans plan to use the legislative vehicle to fund the Department of Homeland Security and its component agencies, principally Immigration and Customs Enforcement (ICE) and Customs and Border Protection (CBP).
The amendment vote put nearly every Senate Republican on the record against a policy supported by President Donald Trump. Last year, Trump signed an executive order directing federal health officials to "communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations."
But experts have noted that, without congressional action giving the federal government more power over drug pricing, pharmaceutical companies would not be required to comply with the proposed targets—rendering Trump's order effectively meaningless. Drug prices have continued to rise in the US despite Trump's order and his outlandish, mathematically impossible claims.
"If Trump is serious about making real change rather than just issuing a press release," Sanders said last year in response to Trump's executive order, "he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks."
The Sanders-led amendment that Republicans blocked on Thursday called for reducing "the price of prescription drugs in the United States by more than 50% by adopting most-favored-nation drug pricing so that the American people pay no more for prescription drugs than Europeans or Canadians."
Research has shown that Americans pay at least twice as much on average for prescription drugs as people in other wealthy nations.
"This amendment is very simple," Sanders said during Senate debate on Thursday. "It would prevent pharmaceutical companies from charging more for prescription drugs in the United States than they do in Canada, the UK, Germany, France, and Japan.”
Last May, Sanders and several of his Democratic colleagues in the Senate introduced the Prescription Drug Price Relief Act, which would require federal health officials to "review brand-name drugs annually for excessive pricing and, if a drug is found to be priced excessively, to void any exclusivity granted to its sponsor."
"Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan," according to a summary of the legislation. "If a price does not meet this criteria, or if pricing information is unavailable in at least three of these countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population."
Keep Reading
Show Less
Defending TrumpRx Scam, RFK Jr. Absurdly Claims Trump 'Has His Own Way of Calculating' Percentages
"You can't just redefine how you calculate percentages," said one mathematician in response to Kennedy's claims.
Apr 22, 2026
US Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday tried to defend President Donald Trump's mathematically absurd claims about prescription drug prices by saying the president has his own unique method of calculating percentages.
During a Senate Finance Committee hearing, Sen. Elizabeth Warren (D-Mass.) grilled Kennedy about the president's repeated false claims that he has slashed the prices of prescription drugs by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
"President Trump has his own way of calculating," Kennedy replied. "There's two ways of calculating percentages. If you have a $600 drug, and you reduce it to $10, that's a 600% reduction."
RFK Jr: "President Trump has a different way of calculating percentages. If you have a $600 drug and you reduce it to $10, that's a 600% reduction." pic.twitter.com/MjDNADqc8p
— Aaron Rupar (@atrupar) April 22, 2026
In fact, such a drop in price would represent a 98.3% reduction, less than one-sixth the size of the president's claims. A 600% reduction in the price of a $600 drug would mean that drug manufacturer paid consumers $3,000 every time they picked up their prescription.
Kit Yates, a mathematician at the University of Bath, marveled at Kennedy's attempts to create an alternate version of arithmetic.
"We've known for a while that the USA's current regime have been out for science, but I never thought they would try to mess with math!" Yates wrote in a social media post. "You can't just redefine how you calculate percentages."
In addition to exposing Kennedy's apparent ignorance of elementary mathematics, Warren shined a light on how the TrumpRx website misleads consumers into thinking they're being offered bargains on prescription drugs that are available elsewhere in generic varieties.
In once instance, Warren noted that TrumpRx is selling a brand-name heartburn medication for $200, whereas a generic version of the same drug is available at Costco for $16. Warren also highlighted a heart arrhythmia drug for sale on TrumpRx for $336, even though a generic version of the drug is available at Costco for $12.
Warren added that, in exchange for making select brand-name drugs available on the TrumpRx website, pharmaceutical companies have gotten exemptions from the president's 100% tariffs on imported patented medicines.
"Think about that: Big Pharma makes billions of dollars in tariff relief by listing their drugs on TrumpRx, and then they don't even lower the costs on many of these drugs," she said. "That is a great deal for Big Pharma."
Warren's analysis of TrumpRx's pricing scheme echoes a March report from the Center for American Progress (CAP), which found that the president's prescription drug website offered genuinely lower prices on “exactly one” of the 54 medications listed.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Reuters reported in December that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
Later in the Senate Finance Committee hearing, Sen. Bernie Sanders (I-Vt.) ridiculed Kennedy for claiming that, under Trump's leadership, "the American people are now paying the lowest costs in the world rather than the highest for prescription drugs."
"That is an absurd statement," Sanders said. "Nobody in the world believes that."
Keep Reading
Show Less
Patient Advocates Warn Trump Pharma Tariffs Could 'Drive Up Costs and Create More Uncertainty'
One campaigner urged the administration to "focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Apr 02, 2026
On Thursday, the one-year anniversary of President Donald Trump's so-called Liberation Day, US advocacy groups sounded the alarm about his new tariffs targeting "patented pharmaceuticals and their ingredients under Section 232 of the Trade Expansion Act of 1962 to bolster American national security and public health."
The administration announced a year ago that the US Department of Commerce would conduct a related investigation under that law. The resulting report was recently sent to the president, and although the findings have not been made public, Trump's executive order summarizes key takeaways and Secretary Howard Lutnick's recommended actions.
According to the order, the secretary's recommendations included "continuing to negotiate onshoring agreements related to most favored nation (MFN) pharmaceutical pricing agreements; imposing significant tariffs on pharmaceuticals and pharmaceutical ingredients, so that such imports will not threaten to impair the national security of the United States; and granting preferential treatment to those companies that commit to onshore production of pharmaceuticals and pharmaceutical ingredients."
Citing an unnamed Trump administration official, The Washington Post reported Thursday that "the White House has reached agreements with 13 drugmakers and expects to soon conclude an additional four." As part of these deals, companies are planning to invest at least $400 billion in new US plants.
The Post also pointed out that "some imported drugs will face much lower tariffs under trade deals Trump negotiated with five US trading partners. Goods from the European Union, Japan, South Korea, and Switzerland will face 15% levies, while drugs from the United Kingdom, which was the first to sign a deal with Trump, will be hit with a 10% tariff."
Thanks to Trump's new order, brand-name pharmaceuticals made in other countries could be hit with tariffs as high as 100%.
Merith Basey, CEO of Patients for Affordable Drugs, warned in a statement that "while these tariffs aim to pressure pharmaceutical corporations into US manufacturing and most favored nation agreements, the current MFN deals remain opaque and voluntary, and have not delivered meaningful savings for the vast majority of American patients. There's a real risk these tariffs will drive up costs and create more uncertainty for millions of patients already struggling to afford their medications."
Experts at Public Citizen, another advocacy group that has sued to expose the secretive MFN agreements, were similarly critical.
"By announcing these tariffs without even producing the evidence from the investigation that supposedly justifies them, Trump is continuing his pattern of grabbing headlines by using the word 'tariff' while engaging in secretive ongoing negotiations and opaque exemptions processes that are ripe for corporate corruption," said Public Citizen Global Trade Watch director Melinda St. Louis—who also wrote a broader takedown of Trump's trade policy published Thursday by Common Dreams.
"While strategic tariffs can be used to support domestic manufacturing and good jobs, they must be paired with real public investments and support for workers' rights, which Trump has systematically undermined," she said. "Instead, he's bullying other countries like the UK into paying more for medicines, which will lead to windfall profits for Big Pharma and do nothing to reduce US prices."
Peter Maybarduk, director of Access to Medicines at Public Citizen, stressed that "Trump's tariffs will be either ineffective or harmful for what people need, which is a reliable, plentiful, affordable supply of medicine."
Also taking aim at the "secretive arrangements that allow Trump to claim specious victories on manufacturing and high drug prices," Maybarduk explained that "in reality, many manufacturing commitments claimed under the deals were part of previously planned projects and the drug pricing commitments appear designed to largely spare drug company profits rather than earnestly address affordability concerns."
"Meanwhile the administration has given drugmakers perks like lucrative vouchers to accelerate FDA review of their medicines and a promise from the Trump administration that it will bully other countries into adopting higher prescription drug prices, using tariffs as leverage," he continued, referring to the Food and Drug administration.
"If the administration wants to fix problems like medicines shortages and fragile supply chains," he argued, "it should focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Keep Reading
Show Less
‘A System Rigged’: Untaxed Wealth of Richest 0.1% Is More Than Assets of World’s Poorest Half
A decade after the Panama Papers, the global rich are still hiding more than $2.8 trillion in tax havens. Just a fraction of that money could end extreme hunger and provide clean water to everyone on Earth.
Apr 02, 2026
The richest 0.1% of people on Earth are hiding more than $2.8 trillion in offshore accounts to avoid taxes. That money alone is more wealth than is owned by the entire bottom half of humanity, more than 4.1 billion people.
These findings were published in a report released Thursday by Oxfam International on the 10th anniversary of the 2016 Panama Papers, which provided an unprecedented look at how the world's most powerful capitalists, financiers, political leaders, celebrities, and criminals exploited offshore tax havens to stash their money.
"Ten years on, the superrich are still sequestering oceans of wealth in offshore vaults,” said Christian Hallum, Oxfam International’s tax lead.
The percentage of untaxed wealth in offshore accounts has dropped in the past 10 years, in large part due to global reforms like the adoption of the Organization for Economic Cooperation and Development's Automatic Exchange of Information framework (AEOI), which allows revenue authorities around the world to easily share information and crack down on cheats.
However, many nations in the Global South are excluded from this system, even though they need the tax revenue the most.
Oxfam found that a staggering $3.5 trillion, more than 3.2% of the global gross domestic product, still remains in untaxed accounts. That's more than the entire GDP of France and is more than twice the combined wealth of the world's 44 poorest nations.
And while the percentage of untaxed wealth is shrinking, that doesn't mean inequality has shrunk.
On the contrary, the December 2025 "World Inequality Report" found that the richest 0.001% of humanity—fewer than 60,000 multimillionaires and billionaires—now have three times as much wealth as the poorest half of the world’s population combined.
Inequality has surged around the world in part due to taxation policies and pandemic recovery packages that overwhelmingly favor the rich. The most glaring was adopted in the world's financial hub, the United States, last year.
The megabudget passed by Republicans and signed into law by President Donald Trump handed a $1 trillion tax cut to America's wealthiest 1% while slashing more than $1 trillion in spending from Medicaid, food assistance, and other safety net programs. It has been described by some economists as the largest upward transfer of wealth in US history.
While the global top 0.1% holds about 80% of untaxed offshore wealth, an even smaller group of uber-wealthy individuals does most of the cheating. The world's richest 0.01%, who hold at least $50 million apiece, control about half of all money in global tax shelters—$1.7 trillion.
According to the Tax Justice Network's Corporate Tax Haven Index, Caribbean islands under UK ownership, including the British Virgin Islands, the Cayman Islands, and Bermuda, are among the worst offenders. Other notable tax havens include Switzerland, Singapore, Hong Kong, Ireland, and the Netherlands.
A February Oxfam report on Elon Musk, who is well on his way to becoming the world's first trillionaire, found that his company, Tesla—which managed to pay zero dollars on its $2.3 billion income in 2024—has not published a country-by-country report on its taxes and that it has subsidiaries in many countries considered to be tax havens.
Big Pharma companies, including AbbVie and Merck, also used tax shelters to lower their total tax expense in 2025 by more than $1 billion, according to a report released earlier this month by the Financial Accountability & Corporate Transparency Coalition.
"This isn’t just about clever accounting—it’s about power and impunity," Hallum said. "When millionaires and billionaires stash trillions of dollars in offshore tax havens, they place themselves above the obligations that bind the rest of society."
"The consequences are as predictable as they are devastating," he continued. "We see our public hospitals and schools starved of funds, our social fabric shredded by rising inequality, and ordinary people forced to shoulder the costs of a system rigged to enrich a tiny few.”
Even a fraction of the money currently stashed away by the world's wealthiest could alleviate untold amounts of suffering.
In November, the United Nations' World Food Program estimated that extreme hunger, which currently affects more than 318 million people around the world, could be eradicated by 2030 with investments of about $93 billion per year, but that global hunger programs instead remain “slow, fragmented, and underfunded."
According to a 2021 UN Educational, Scientific, and Cultural Organization (UNESCO) report, investments of around $114 billion per year would similarly be enough to ensure that everyone on Earth has access to safe drinking water and sanitation.
Oxfam called on governments around the world to increase coordination to prevent the wealthy from hiding their riches from tax authorities. It also urged them to adopt more aggressive policies to tax the 1%'s wealth at home, including taxes on income and on extreme wealth.
Keep Reading
Show Less
In Leaked Video, Maine Voters Challenge Mills on Vetoes, Gun Control, and More
One voter told the Maine governor, who is running for US Senate, that she is wondering "why you would fight on behalf of us on the national level if you couldn't do it on the state level."
Mar 24, 2026
Most of the national news surrounding the Maine Democratic Senate primary has zeroed in on candidate Graham Platner's record—a tattoo he got while serving in the Marines and posts he wrote several years ago on Reddit.
But a video recording obtained by Drop Site News of a local Democratic group's Zoom meeting last week with Platner's main opponent, Gov. Janet Mills, brought to light discussions Maine voters are having not about the first-time candidate's controversies—which have done little to damage his campaign, according to numerous polls—but about the record of the governor who's run the state for the last six years.
For 30 minutes on March 19, members of the Hancock County Democrats grilled Mills about her history of vetoing significant pieces of legislation and opposing measures broadly supported by Mainers.
⚡️Leaked Video: Janet Mills Attack Ad Against Graham Platner Backfires With Maine Democrats
A Zoom recording with Gov. Janet Mills captures unfiltered voter reactions to the governor’s recent attack ad against her U.S. Senate primary opponent, Graham Platner.
Story by… pic.twitter.com/xF6bmqDsAf
— Drop Site (@DropSiteNews) March 23, 2026
A former Democratic state representative, Mark Worth, asked Mills early in the question-and-answer session about her "record on tribal sovereignty, labor, and gun safety bills, such as your veto of the red flag law"—an apparent reference to Mills' opposition to the red flag law that was passed by referendum in 2025, with 62% supporting the measure to make it easier for law enforcement to take away someone's firearm if they pose a threat to themself or others.
Mills instead supported the state's "yellow flag law," which requires police to take a person into custody and obtain an assessment by a mental health professional before a gun can be taken away.
Nearly two dozen states and the District of Columbia have red flag laws, also known as extreme risk protection orders, and they are supported by 77% of Americans, including a majority of gun owners and Republicans, according to an APM Research Lab/Guns & America/Call To Mind poll from 2019.
Mills responded to the question by defending gun control legislation that has passed in Maine during her tenure—including a ban on ghost guns and expanded background checks—but did not mention the broadly popular red flag law that she opposed.
She said that she had sought to find "common ground" between gun control advocates and gun owners—even though the referendum was supported by nearly two-thirds of voters, including many gun owners—one of whom was Platner, a combat veteran.
The governor has also been criticized for vetoing a bill that would have barred the state from seizing tribal lands, and has angered the state's labor movement several times, including when she vetoed an offshore wind development bill due to her opposition to an amendment requiring collective bargaining agreements, and another measure that would have allowed farmworkers to unionize.
At the meeting this month, a voter named Diana Morenda introduced herself as a "three-time cancer veteran" and asked about two other vetoes by the governor—those of LD 765, which aimed to prohibit "unsupported price increases" of prescription drugs, and LD 1117, which would have prohibited excessive rises in the price of generic prescription drugs.
With the vetoes, Morenda told Mills, she "essentially destroyed any chance that your constituents would have had to combat excessive pricing, kind of siding with Big Pharma."
"You can understand why I... and many others in Hancock County, we might be wondering out loud why you would fight on behalf of us on the national level if you couldn't do it on the state level," said Morenda.
Mills responded similarly as she had to the earlier question, naming other moves she's taken to increase access to prescription drugs and price transparency and telling the voter, "Whoever gave you those two numbers didn't give you the rest of the bills that we did pass."
The controversies surrounding Platner's campaign came up during the meeting, with Worth telling Mills her recent attack ad against Platner was "divisive and odious," and another voter accusing the governor of "using underhanded means" against her opponent.
The ad included several women looking at posts Platner wrote in 2013 disparaging sexual assault survivors. Platner has addressed his old online comments several times, saying his views have evolved since he wrote them.
One voter disclosed that he is a friend of Platner's before asking Mills: "Do you believe in a Maine and a country where a person can be redeemed? Where they can change and become a better version of themself?"
Mills deflected the question, claiming that her concern is not "whether he's reformed or thinks better," but electability.
"The issue is who can beat Susan Collins," said Mills, referring to the state's Republican senator.
The governor has persistently claimed that she has the greatest chance of beating Collins in November, contrary to several polls.
The voter addressed those claims in his question.
"You say electability is what you're looking for here," he said. "And if you truly do believe that and you've read the polls—which I imagine you have—that isn't the case."
Keep Reading
Show Less
As TrumpRx Scam Does Virtually Nothing, Big Pharma Jacks Up Prices on Cancer Drugs
"As they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them, and patients are paying the price."
Mar 23, 2026
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Keep Reading
Show Less
Congressional Report Warns TrumpRx May Lead 'Families to Pay More to Big Pharma'
"The president should work with Democrats and Republicans to actually lower prescription drug costs for families," said Sen. Maggie Hassan, "rather than helping Big Pharma line its pockets."
Feb 13, 2026
Democratic members of the congressional Joint Economic Committee on Friday released a report warning that US families could end up spending thousands of dollars more on prescription drugs because of a website recently unveiled by President Donald Trump.
Launched last week with pharmaceutical companies, TrumpRx.gov is marketed as an aggregator to help patients save on prescription drugs by using manufacturer coupons or buying directly from manufacturers.
However, as the new report highlights, "many of the brand-name drugs listed on TrumpRx have significantly cheaper generic alternatives, which are excluded from TrumpRx. This means that TrumpRx steers families to pay more to Big Pharma when they could be getting the same medication at a much lower price."
"No matter what the president says, the bottom line is that TrumpRx directs families to buy expensive brand-name drugs when generic versions are available elsewhere at a fraction of the cost."
The report provides a chart comparing TrumpRx and generic prices, both for one prescription fill and the full annual cost. It also notes the difference. In some cases, the president's option is $10-50 more a year. However, there are also examples in which families could save hundreds or thousands of dollars with generic drugs.
For example, Colestid, a medication that lowers cholesterol, would cost $2,771.21 a year through TrumpRx, compared with $856.70 for the generic option, a difference of $1,914.51. The antidepressant Pristiq is $2,401.20 on the president's website, versus just $320.88 for the generic, a potential yearly savings of $2,080.32.
The biggest difference featured in the document is for Tikosyn, which helps patients maintain a normal heart rhythm. The TrumpRx annual cost is $4,032, whereas the generic is only $192.68, a difference of $3,839.32.
The report also stresses how extra costs from the president's site could stack up for households in which multiple people need medication:
- For example, if in one family a parent gets treatment for high cholesterol and their child gets treated for seizures, over the course of 2026 this family would pay $2,142 more if they use TrumpRx versus generic drug alternatives.
- For another family where one adult gets treatment for depression while the other receives treatment for menopause symptoms, over the course of 2026 this family would pay $2,493 more if they use TrumpRx versus generic drug alternatives.
"No matter what the president says, the bottom line is that TrumpRx directs families to buy expensive brand-name drugs when generic versions are available elsewhere at a fraction of the cost," said Sen. Maggie Hassan (D-NH), ranking member of the Joint Economic Committee and the Senate Finance Subcommittee on Health Care.
"The president should work with Democrats and Republicans to actually lower prescription drug costs for families," Hassan argued, "rather than helping Big Pharma line its pockets."
While the Trump White House responded defensively to the Democratic report, with spokesperson Kush Desai claiming to MS NOW that "product listings on TrumpRx.gov are in no way an endorsement for use of any prescription drug over another" and accusing Democrats of "resorting to idiotic or simply ignorant lines of attack instead of simply giving the president credit where it's due," the panel members aren't alone is highlighting such cost differences.
The added cost for US families also isn't lawmakers' only concern about TrumpRx. Last month, shortly before the site's launch, Democratic Sens. Dick Durbin (Ill.) Elizabeth Warren (Mass.), and Peter Welch (Vt.) sent a letter to the US Department of Health and Human Services Office of Inspector General raising concerns about the new direct-to-consumer (DTC) platform.
"There appear to be possible conflicts of interest involved in the potential relationship between TrumpRx and an online dispensing company, BlinkRx, on whose board the president's son, Donald Trump Jr., has sat since February 2025," they wrote. "Moreover, legitimate concerns about inappropriate prescribing, conflicts of interest, and inadequate care have been raised about the exact types of DTC platforms to which TrumpRx would route patients."
The trio also expressed alarm about high prices, noting that "pharmaceutical manufacturers who will reportedly be participating in TrumpRx have spent billions of dollars in combined advertising expenses for drugs sold on existing DTC platforms."
"The pharmaceutical industry's outrageous DTC advertisements fuel demand for specific medications, which balloon healthcare expenses," the senators wrote. "We are concerned that DTC advertising, including in relation to TrumpRx, will steer customers to prescriptions that may be reimbursed by federal health programs, creating the potential for unnecessary or wasteful spending."
Keep Reading
Show Less
TrumpRx Denounced as Corrupt Scheme to Line Pockets of Big Pharma—and Don Jr.
"Trump has dressed up yet another corporate giveaway as a boon to patients," said one watchdog. "Real drug price reform doesn’t look like a website."
Feb 06, 2026
US President Donald Trump on Thursday launched a website, branded with his name, in a purported effort to help patients buy prescription drugs at lower prices.
But experts, watchdog groups, and Democratic lawmakers said TrumpRx will likely do little for consumers—or for the broader goal of bringing down exorbitant medicine costs—while further enriching Big Pharma and potentially lining the pockets of his eldest son, Donald Trump Jr.
TrumpRx.gov, launched in partnership with pharmaceutical giants, points users to direct-to-patient sales platforms hosted by drug companies to facilitate the purchase of an extremely limited selection of medications. For example, TrumpRx's listing for Farxiga links users to AstraZeneca Direct, where patients can pay out of pocket for the type 2 diabetes medication.
Donald Trump Jr. is on the board of BlinkRx, a prescription drug platform that stands to benefit from the Trump administration's promotion of direct-to-patient medicine sales. In December, the president's son reportedly met with top drug company executives and administration officials responsible for regulating the pharmaceutical industry—a gathering hosted by BlinkRx.
Frank Pallone Jr. (D-NJ), the top Democrat on the House Energy and Commerce Committee, said in a statement Thursday that TrumpRx "not only threatens patients’ health, safety, and privacy, but also likely includes kickback schemes designed to enrich President Trump, his family, and their friends."
"TrumpRx has been shrouded in secrecy from the beginning because the administration clearly does not want anyone to know it likely won’t save patients money," said Pallone. "However, we do know Trump only slaps his name on things when there’s something in it for him."
Last week, a group of Democratic senators sent a letter to the inspector general of the US Department of Health and Human Services warning that "without stricter safeguards before its official launch, TrumpRx could be used as a potential vehicle for unlawful kickback schemes that result in excessive costs for the federal government."
In addition to sending users to direct-to-patient sales sites, TrumpRx offers Trump-branded coupons for some medications. To obtain a coupon, site users must accept terms that state: "You agree that by redeeming this coupon, you (and anyone else acting on your behalf) agree not to seek reimbursement from any insurance plan for out-of-pocket costs for prescriptions purchased with this coupon. You also agree not to count the cost of prescriptions toward your deductible or true out-of-pocket costs."
The Washington Post reported that pharmaceutical companies "have agreed to list their drugs on TrumpRx.gov."
"TrumpRx is designed to help Big Pharma keep its prices high by diluting the bargaining power of insurance companies, weakening an important check on pharma."
Experts warned that patients who use TrumpRx could end up paying more for their medications than if they pursued other available options.
"TrumpRx’s offerings are very limited, fewer than 50 drugs listed, and most are niche products used by few patients," Rena Conti, an associate professor at Boston University, told ABC News. "Many are available in generic form at even lower prices or already available to consumers at low or even very low prices elsewhere. This suggests it pays for consumers to check their insurance coverage and ask their regular doctor or pharmacist before they use this service."
Peter Maybarduk, access to medicines director at Public Citizen, offered a more scathing assessment of TrumpRx, saying the president has "dressed up yet another corporate giveaway as a boon to patients."
"Most patients will do better through their insurance than through TrumpRx. Many patients without insurance will not be able to afford drugmakers’ still-high prices funneled through TrumpRx," said Maybarduk. "But drugmakers certainly will appreciate TrumpRx’s free promotion of their products, delivered with a false veneer of price accountability. TrumpRx is designed to help Big Pharma keep its prices high by diluting the bargaining power of insurance companies, weakening an important check on pharma."
“TrumpRx also appears to be another example of this president’s repeated corruption," he continued. "Trump’s son, Donald Trump Jr., sits on the board of BlinkRx, a key business that may benefit financially from TrumpRx. Getting serious about medicine affordability means getting serious about challenging Big Pharma. For all Trump’s talk, Big Pharma is getting a lot of special favors from this White House, while patients still are waiting. Real drug price reform doesn’t look like a website."
Throughout his second White House term, Trump has made outlandish promises to cut drug costs and hosted top executives at the White House to tout splashy deals—only for pharmaceutical giants to continue jacking up prices. Reuters reported last month that drugmakers planned to "raise US prices on at least 350 branded medications, including vaccines against Covid, RSV, and shingles and blockbuster cancer treatment Ibrance" in 2026.
Merith Basey, CEO of Patients for Affordable Drugs Now, said in a statement that the Trump administration's "voluntary agreements" with drug companies "lack clear enforcement mechanisms and still put the power to set and increase prices firmly in the hands of pharmaceutical corporations."
"Patients in our community will soon learn if they can reliably access these discounts at the pharmacy counter, where the program will ultimately be tested and where affordability matters most," Basey said of TrumpRx.
Keep Reading
Show Less
Senate Democrats Expose Trump's Latest 'Fraud' and Lay Out Plan to Reduce Drug Costs as Prices Surge
"When Big Pharma gets richer off the back of a grandmother struggling to pay for cancer medication, the system is broken."
Feb 04, 2026
Led by Senate Finance Committee Chair Ron Wyden, four Democratic senators on Wednesday outlined plans to reduce the costs of prescription drugs after President Donald Trump claimed he would do so—only to allow Big Pharma companies to delay negotiating lower prices and secure "zero commitments" from top executives on making lifesaving medications more affordable for millions of Americans.
“There is no greater fraud than Donald J. Trump when it comes to lower drug prices,” Wyden (D-Ore.) said. “Our doors are wide open to anybody who wants to take the bold next step forward on lowering drug costs for Americans."
Along with a "flash report" on Trump's "broken promises" regarding his pledge to bring drug prices down “to levels nobody ever thought was possible," Wyden sent a Dear Colleague letter to Democratic senators regarding his committee's plans to follow through with lowering costs.
"Finance Committee minority staff will dedicate substantial time and effort this year to developing the next generation of healthcare solutions that lower costs for American families," Wyden wrote. "These solutions will rein in Big Pharma’s outrageous price increases, lower costs for consumers, guarantee predictability for patients, and reduce wasteful government spending that pads the profits of big corporations. Alongside the co-signers of this letter, I invite you to be a part of this bold vision."
The letter, co-signed by Sens. Catherine Cortez Masto (D-Nev.), Peter Welch (D-Vt.), and Ruben Gallego (D-Ariz.), notes that "the only concrete drug pricing policy Trump enacted within the past year was a price hike for the biggest blockbuster cancer drugs on Earth, giving an $8.8 billion windfall to the pharmaceutical industry."
In contrast, the senators wrote, the Senate Finance Committee will develop policies to incorporate international pricing models into the Medicare drug price negotiation framework, including by allowing Health and Human Services Secretary Robert F. Kennedy Jr. to consider international prices as a factor or penalize drugmakers when pricing for US customers exceeds international benchmarks.
“Democrats are determined to bring prices down, and we’re willing to work with anyone to find concrete ways to do it."
The committee will also work to end Republican "blockbuster drug bailouts from negotiation," like the ones included in the One Big Beautiful Bill Act that shielded several high-priced drugs—including the cancer drug Keytruda—from Medicare price negotiations.
"The Republican budget bill contained a nearly $9 billion sweetheart deal that benefits the biggest drug companies by delaying or exempting some lifesaving medications from negotiation," reads the Democrats' flash report.
Gallego said that "when Big Pharma gets richer off the back of a grandmother struggling to pay for cancer medication, the system is broken."
"That’s what this is all about: Big Pharma execs sitting in their fancy corner offices profiting off of sick, working-class Americans,” the senator said. “We are not going to accept an America where millions of families live in fear of getting sick and needing to fill a prescription. We are going to fight and fight hard for a healthcare system that does what Donald Trump never did: actually lower costs for working families.”
The lawmakers emphasized that even if manufacturers are forced to lower drug prices, patients are not currently guaranteed to directly benefit, because as much as 45% of the $5.4 trillion the US spends on healthcare annually is "absorbed by middlemen such as insurers, pharmacy benefit managers (PBMs), and drug distributors."
"Healthcare middlemen profit when drug costs are high because they make money off of drug margin or payments that are linked to the price of a drug, ripping off patients who pay more than they should. Medicare Part D and the patients it serves should stop footing the bill for inflated drug prices and instead pay for drugs in a more transparent manner that reduces middleman margin," wrote the senators.
The Finance Committee will develop policies to eliminate abuses in the prescription drug supply chain including "egregious drug price markups," and to ensure that patient cost-sharing on drugs more closely aligns with the costs to plans and PBMs.
Finally, the Democrats said they would work to fix the "unmitigated disaster" that Trump and Kennedy have been "for innovation and drug development," as the administration has proposed slashing the National Institutes of Health budget by 40% and has cut off access to treatment for an estimated 74,000 patients who were enrolled in NIH clinical trials.
The Finance Committee, they said, plans to create new incentives for innovation and drug development, including through the tax code.
In their flash report, the Democrats wrote that while failing to force Big Pharma to the negotiating table to save money for Americans, Trump "has been parading Big Pharma executives through the White House, claiming to be cutting cost-saving deals with these corporations."
"One look under the hood reveals the truth: Trump is giving them a pass on tariffs, while receiving zero commitments about how they will lower costs for taxpayers and patients," they wrote. "Donald Trump is getting fleeced by Big Pharma CEOs, and Americans are going to foot the bill."
Welch said that the president "loves to talk a big game and make promises to working families about lowering prescription drug prices. But in reality, his administration is handling this like a PR problem: They’ve got to keep moving and talking about it, but then do nothing to really address the crisis."
“Democrats are determined to bring prices down, and we’re willing to work with anyone to find concrete ways to do it," said Welch. "We’re going to lower healthcare costs and ensure everyone can access affordable, lifesaving, and pain-relieving medication.”
Keep Reading
Show Less
As Trump Claims He's Slashing Costs, Big Pharma Jacks Up Prices on 350 Drugs
One critic charged that Trump's earlier deals with pharmaceutical companies "just nibble around the margins in terms of what is really driving high prices for prescription drugs in the US."
Dec 31, 2025
President Donald Trump in recent months has made ludicrously false claims about his administration slashing prescription drug prices in the US by as much as 600%, which would entail pharmaceutical companies paying people to use their products.
In reality, reported Reuters on Wednesday, drugmakers are planning to raise prices on hundreds of drugs in 2026.
Citing data from healthcare research firm 3 Axis Advisors, Reuters wrote that at least 350 branded medications are set for price hikes next year, including "vaccines against COVID, RSV, and shingles," as well as the "blockbuster cancer treatment Ibrance."
The total projected number of drugs seeing price increases next year is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications.
The median price increase for drugs next year is projected at 4%, roughly the same as in 2025.
Reuters also found that some of the companies raising prices on their drugs are the same ones who struck deals with Trump to lower the costs of a limited number of prescriptions earlier this year, including Novartis, Pfizer, Boehringer Ingelheim, and GSK.
In announcing the deals with the pharmaceutical companies, Trump declared that "starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world."
But Dr. Benjamin Rome, a health policy researcher at Brigham and Women's Hospital in Boston, told Reuters that the projected savings for Americans under the Trump deals are a drop in the bucket compared with the continued price hikes on other drugs.
"These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the US," Rome explained.
Merith Basey, CEO of Patients For Affordable Drugs Now, a patient advocacy organization focused exclusively on lowering the cost of medications, also said she was unimpressed by Trump's deals with drugmakers.
"Voluntary agreements with drug companies—especially when key details remain undisclosed—are no substitute for durable, system-wide reforms," she said earlier this month. "Patients are overwhelmingly calling on Congress to do more to lower prescription drug prices by holding Big Pharma accountable and addressing the root causes of high drug prices, because drugs don’t work if people can’t afford them."
Keep Reading
Show Less
See More Stories
Most Popular
To inform. To inspire. To ignite change for the common good.
News & Opinion
Trending
Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit
Privacy Policy